YAVNE, Israel, November 5, 2025 — Leads & Copy — MediWound Ltd. (Nasdaq: MDWD) will release its third quarter financial results on Thursday, November 20, 2025, followed by a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.
The company’s management will host the call, with dial-in details provided for toll-free, Israel, and international participants, as well as a webcast link. An archived version will be available on the Investors section of the MediWound website.
MediWound Ltd. is a global biotechnology company focused on enzymatic therapies for non-surgical tissue repair. Its FDA-approved biologic, NexoBrid®, is for eschar removal in thermal burns and is marketed internationally. The company is also advancing EscharEx®, a late-stage therapy for debridement of chronic wounds.
MediWound Contacts:
Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Ellie Hanson
Partner
FINN Partners for MediWound
ellie.hanson@finnpartners.com
Source: MediWound Ltd.
